Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- REPORT
July 3, 2006
- Korosho Has Budget to Conduct Market Price Survey This Year: HIB Official
July 3, 2006
- TOPICS 2 articles
July 3, 2006
- Ryukaikon Resumes Discussions
July 3, 2006
- Concern Expressed about Qualifications of New "Registered Drug Sellers"
July 3, 2006
- LDP Starts Discussions on Further
June 26, 2006
- Taisho, Abbott Japan: Clarith/Klaricid Dry Syrup for Children
June 26, 2006
- Drug Firms' Stock Prices Plummet on News of Another Price Cut
June 26, 2006
- American Society of Clinical Oncology (ASCO) 2006: 2
June 26, 2006
- SEMINAR
June 26, 2006
- Astellas, Pfizer Make Strongest
June 26, 2006
- Teijin Aims for Sales of \120 Bil.
June 26, 2006
- PMDA Places Top Priority on
June 26, 2006
- Takeda Ties-Up with Cephalon
June 26, 2006
- JPMA
June 26, 2006
- Mediceo Paltac to Acquire
June 26, 2006
- NEW PRODUCTS
June 26, 2006
- Lilly Initiates PIII Study
June 26, 2006
- Amended PAL Will Create New Business
June 26, 2006
- HMW Fucoidan Inhibits
June 26, 2006
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…